Management of Fulminant Multiple Sclerosis with Rituximab: A Case Report  

Oleh:

Parfenov, Valeriy ; Du Pasquier, Renaud ; Schluep, Myriam

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Neurologist vol. 19 no. 06 (Jun. 2015), page 155-157.
Topik: Fulminant Multiple Sclerosis; Rituximab; Fingolimod

Ketersediaan

Perpustakaan FK Nomor Panggil: N06.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Introduction: Malignant variant is a rare subtype of multiple sclerosis (MS) that is rapidly progressive and may lead to significant disability or even death. No consensus exists on best management of this disorder, although corticosteroids and plasmapheresis are commonly used in the acute phase, followed either by MS-specific disease-modifying therapy or an immunosuppressant. Case Report: The patient is a 30-year-old man with relapsing-remitting MS previously well controlled with natalizumab, who has developed fulminant disease activity upon natalizumab cessation. In the acute phase, patient had a suboptimal response to multiple corticosteroid treatments but responded very well to plasmapheresis. Patient continued to have worsening disease activity despite fingolimod treatment. Disease control has been eventually achieved by switching to rituximab. Conclusion: Rituximab treatment should be considered for a patient with fulminant MS who responded well to plasmapheresis.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali